$MXCT

MAXCYTE, INC. (MXCT): Submission of Matters to a Vote of Security Holders

MAXCYTE, INC. (MXCT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. MaxCyte, Inc._June 17, 2026 0001287098 false 0001287098 2026-06-17 2026-06-17 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ​ FORM 8-K ​ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ​ Date of Report (Date of e

Original reporting
Published Jun 17, 2026, 8:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$MXCT
Neutral
high confidence
Mentioned
$MXCT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MXCTNeutralLow
01

Why it matters

The disclosure confirms shareholder approval of directors and the independent registered public accounting firm for fiscal year ending December 31, 2026, but does not change fundamentals.

02

Market read

Primarily administrative governance information; not a catalyst for earnings, guidance, or major corporate events.

03

What to watch

If there were contested director elections or auditor disputes, vote counts could matter; here, the filing provides no indication of controversy or outcomes beyond standard approval.

Relevance 6/10Novelty 2/10Timing: Filed June 17, 2026 (after market hours)

Background

Form 8-K Item 5.07 is used to report matters submitted to a vote of security holders following an annual meeting.

Company-level read

Ticker impact

$MXCTNeutralHigh confidence
Context

MaxCyte’s 8-K reports stockholder voting results: election of Class II directors and ratification of CohnReznick as FY2026 auditor.

Expected impact

Low likelihood of sustained price impact; any reaction is likely limited to short-term sentiment around governance items.

Evidence & confidence

The filing only tallies votes at the June 17, 2026 annual meeting and does not introduce new strategy, financial results, or material transactions.

Market effects

No meaningful read-across to the biotech/bioprocessing tools sector from this governance-only vote tally.

None.

None.

Counterpoint

Traders could treat auditor ratification as a minor positive for governance continuity, but the disclosure lacks any change in audit scope or financial reporting risk.

Key entities

  • MaxCyte, Inc.

    Subject of the 8-K; reports annual meeting voting results for director election and auditor ratification.

  • CohnReznick LLP

    Ratified as MaxCyte’s independent registered public accounting firm for FY ending Dec. 31, 2026.

Related articles

Med

MaxCyte, Inc. Q2 2026 Earnings Call Summary

MaxCyte reported Q2 2026 sequential revenue growth after inventory drawdowns from a major customer and clinical program discontinuations. It signed a multi-platform enterprise partnership with Genentech and expects 2026 revenue guidance of $30m to $32m. Operating expenses fell 25% YoY. Company plans to use most of a $10m share repurchase program and expects mid-70s gross margins.

$MXCTMedAI 8/10

MaxCyte narrows Q2 2026 loss 28%, signs Genentech deal

MaxCyte Inc (NASDAQ: MXCT) reported Q2 2026 EPS of $(0.08), better than the $(0.09) consensus, and revenue of $7.271M versus $6.475M consensus. Sales fell 14.53% year over year. The company signed a multi-platform technology license partnership with Genentech and reiterated 2026 guidance for $30M to $32M revenue.

$MXCTMed

MAXCYTE, INC. (MXCT): Results of Operations and Financial Condition

MAXCYTE, INC. (MXCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ MaxCyte Reports Second Quarter 2026 Financial Results · Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue · Reiterates Full Year 2026 Guidance · Repurchased a

$BABAMedAI 8/10

ByteDance, Tencent, Alibaba & Baidu Take On Heavy Debt to Bet on AI: The Survival Multiple

Chinese tech giants ByteDance, Alibaba, Tencent, and Baidu are taking on heavy debt to invest in AI computing power. ByteDance reported $1.2T revenue and $200B net profit in H1 2026, but borrowed $296B. Tencent issued $47B in bonds and saw negative free cash flow. Alibaba completed an $80B share placement. These companies are shifting from asset-light to asset-heavy models due to AI's capital-intensive nature.

Med

Jeld-Wen Holding Inc

Jeld-Wen Holding Inc. is negotiating with creditors for an amend-and-extend deal, potentially including new capital from unsecured creditors to gain secured status. First-lien lenders can roll positions or accept repayment at a discount. The company reported a 0.7% revenue decline and a net loss of $31.5 million in Q2, with total debt of $1.25 billion. Unsecured debt prices have risen, reflecting investor interest.